CANCER THERAPY: PRECLINICAL

2850 Lyn Kinase Mediates Cell Motility and Tumor Growth in EGFRvIII-Expressing Head and Neck Cancer
Sarah E. Wheeler, Elena M. Morariu, Joseph S. Bednash, Charlton G. Otte, Raja R. Seethala, Simonion I. Chiosea, and Jennifer R. Grandis

2861 L-BLP25 Vaccine plus Letrozole Induces a Th1 Immune Response and Has Additive Antitumor Activity in MUC1-Expressing Mammary Tumors in Mice
Neelima R. Mehta, Gregory T. Wurz, Rebekah A. Burich, Brittany E. Greenberg, Stephen Griffey, Audrey Gutierrez, Katie E. Bell, Jamie L. McCall, Michael Wolf, and Michael DeGregorio

IMAGING, DIAGNOSIS, PROGNOSIS

2872 Tumor Infiltrating Immune Cells and Outcome of Merkel Cell Carcinoma: A Population-Based Study
Harri Sihto, Tom Böhling, Heli Kavola, Virve Koljonen, Marko Salmi, Sirpa Jalkanen, and Heikki Joensuu

2882 Global Methylation Profiling for Risk Prediction of Prostate Cancer
Saswati Mahapatra, Eric W. Kleer, Charles Y.F. Young, Zhifu Sun, Rafael E. Jimenez, George G. Klee, Donald J. Tindall, and Krishna Vanaja Donkena

2896 Correlation of ERG Expression and DNA Methylation Biomarkers with Adverse Clinopathologic Features of Prostate Cancer
Ken Kron, Liyang Liu, Dominique Trudel, Vaijayanti Pethe, John Trachtenberg, Neil Fleshner, Bharati Bapat, and Theodorus van der Kwast

CANCER THERAPY: CLINICAL

2905 Metformin Use Is Associated with Better Survival of Diabetic Patients with Pancreatic Cancer
Navid Sadeghi, James L. Abbuzzese, Sai-Ching J. Yeung, Manal Hassan, and Donghui Li

Pharmacokinetics and Repolarization Effects of Intravenous and Transdermal Granisetron
Jay W. Mason, Daniel S. Selness, Thomas E. Moon, Bridget O’Mahony, Peter Donachie, and Julian Howell

Survival of 1,181 Patients in a Phase I Clinic: The MD Anderson Clinical Center for Targeted Therapy Experience
Jennifer Wheleer, Apostolia M. Tsimberidou, David Hong, Aung Naing, Gerald Falchook, Sarina Piha-Paul, Siqing Fu, Stacy Moulder, Betzty Stephen, Sijin Wen, and Razelle Kurzrock

Microarray Analysis Verifies Two Distinct Phenotypes of Glioblastomas Resistant to Antiangiogenic Therapy

Analysis of Spontaneous Tumor-Specific CD4 T-cell Immunity in Lung Cancer Using Promiscuous HLA-DR Telomerase-Derived Epitopes: Potential Synergistic Effect with Chemotherapy Response

Pharmacokinetics and Safety of Bortezomib in Patients with Advanced Malignancies and Varying Degrees of Liver Dysfunction: Phase I NCI Organ Dysfunction Working Group Study NCI-6432
Gender Influences the Class III and V β-Tubulin Ability to Predict Poor Outcome in Colorectal Cancer
Marisa Mariani, Gian Franco Zannoni, Stefano Sioletic, Steven Sieber, Candice Martino, Enrica Martinelli, Claudio Coco, Giovanni Scambia, Shohreh Shahabi, and Cristiano Ferlini

An Apoptosis Methylation Prognostic Signature for Early Lung Cancer in the IFCT-0002 Trial
Florence de Fraipont, Guénaële Levallet, Christian Creveuil, Emmanuel Bergot, Michèle Beau-Faller, Mounia Mounawar, Nicolas Richard, Martine Antoine, Isabelle Rouquette, Marie-Christine Favrot, Didier Debieuvre, Denis Braun, Virginie Westeel, Elisabeth Quoix, Elisabeth Brambilla, Pierre Hainaut, Denis Moro-Sibilot, Franck Morin, Bernard Milleron, and Gérard Zalcman on behalf of the Intergroupe Francophone de Cancérologie Thoracique (IFCT)

Prognostic and Predictive Role of JWA and XRCC1 Expressions in Gastric Cancer
Shouyu Wang, Xuming Wu, Yansu Chen, Jianbing Zhang, Jingjing Ding, Yan Zhou, Song He, Yongfei Tan, Fulin Qiang, Jin Bai, Jinyan Zeng, Zhenghua Gong, Aiping Li, Gang Li, Oluf Dimitri Roe, and Jianwei Zhou

ABOUT THE COVER
Methylation of the tumor suppressor gene Ras association domain family 1A (RASSF1A) is an independent adverse prognostic factor in patients with early-stage non–small cell lung carcinoma treated in the phase III trial on perioperative chemotherapy, IFCT-0002. The cover image is a photomicrograph showing RASSF1A protein distribution in immortalized interphasic bronchial epithelial cells, HBEC3, using confocal microscopy. RASSF1A is stained in red (Alexa-fluo red-labeled secondary antibody). Nuclei are shown in light purple (DAPI). For details, see the article by de Fraipont and colleagues on page 2976 of this issue.